Successful IMPD within CNS therapeutics

TKT has successfully contributed to an IMPD application from Integrative Research Laboratories (IRL) to the Swedish MPA. The toxicology and safety pharmacology parts, which TKT was responsible for, were approved without comments from the MPA. First dose to man will be administered in the beginning of December 2015. For more information: